Bellicum Pharmaceuticals Inc Watch

from 8-K 2 pages Amendment No. 1 to Consulting Agreement

from 10-Q 1 page Amendment to Consulting Agreement

from 8-K 1 page Amendment to Consulting Agreement

from 10-Q 8 pages Consulting Agreement

from 10-Q 8 pages Consulting Agreement

from 10-K 25 pages Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan Adopted by the Compensation Committee of the Board of Directors: April 22, 2019 Approved by the Stockholders: June 13, 2019 Amended and Approved by the Board of Directors: July 9, 2019 Amended by the Board of Directors: December 2, 2019 Approved by the Stockholders: January 15, 2020 Amended by the Board of Directors: April 16, 2020 Amended by the Board of Directors: April 22, 2020 Approved by the Stockholders: June 15, 2020 Amended by the Board of Directors: July 23, 2020 Amended by the Compensation Committee of the Board of Directors: November 10, 2020 Amended by the Board of Directors: April 15, 2021 Approved by the Stockholders: June 15, 2021 Amended by the Compensation Committee of the Board of Directors: March 25, 2022 Approved by the Stockholders: June 15, 2022 Amended by the Compensation Committee of the Board of Directors: January 6, 2023

from 10-Q 3 pages Bellicum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy

from 8-K 25 pages Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan Adopted by the Compensation Committee of the Board of Directors: April 22, 2019 Approved by the Stockholders: June 13, 2019 Amended and Approved by the Board of Directors: July 9, 2019 Amended by the Board of Directors: December 2, 2019 Approved by the Stockholders: January 15, 2020 Amended by the Board of Directors: April 16, 2020 Amended by the Board of Directors: April 22, 2020 Approved by the Stockholders: June 15, 2020 Amended by the Board of Directors: July 23, 2020 Amended by the Compensation Committee of the Board of Directors: November 10, 2020 Amended by the Board of Directors: April 15, 2021 Approved by the Stockholders: June 15, 2021 Amended by the Compensation Committee of the Board of Directors: March 25, 2022 Approved by the Stockholders: June 15, 2022

from S-3 3 pages Bellicum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy

from 10-K 17 pages Bellicum Pharmaceuticals, Inc. Amended and Restated Employment Agreement This Amended and Restated Employment Agreement (The “Agreement”) Dated as of November 3, 2021, Is Entered Into by and Between Bellicum Pharmaceuticals, Inc. a Delaware Corporation, Having a Location at 3730 Kirby Drive, Suite 1200, Houston, Texas 77098 (The “Company”) and Charity Scripture, Ms, Pharmd, Bcop. (The “Executive”). Whereas, Company and Executive Are Parties to That Certain Employment Agreement Dated June 19, 2020 as Amended on September 14, 2020 and January 1, 2021 (The “Original Employment Agreement”);

from 10-K 23 pages Execution Version

from 8-K 44 pages Securities Purchase Agreement

from 10-Q 20 pages Certain Information Contained in This Exhibit, Marked by [***], Has Been Excluded From This Exhibit Because Bellicum Pharmaceuticals, Inc. Has Determined That It Is Both Not Material and Is the Type That Bellicum Pharmaceuticals, Inc. Treats as Private or Confidential. License Agreement

from 8-K 28 pages Bellicum Pharmaceuticals, Inc. 2019 Equity Incentive Plan Adopted by the Compensation Committee of the Board of Directors: April 22, 2019 Approved by the Stockholders: June 13, 2019 Amended and Approved by the Board of Directors: July 9, 2019 Amended by the Board of Directors: December 2, 2019 Approved by the Stockholders: January 15, 2020 Amended by the Board of Directors: April 16, 2020 Amended by the Board of Directors: April 22, 2020 Approved by the Stockholders: June 15, 2020 Amended by the Board of Directors: July 23, 2020 Amended by the Compensation Committee of the Board of Directors: November 10, 2020 Amended by the Board of Directors: April 15, 2021 Approved by the Stockholders: June 15, 2021

from 10-Q 3 pages Bellicum Pharmaceuticals, Inc. Non-Employee Director Compensation Policy

from 10-K 61 pages Bellicum Pharmaceuticals, Inc. Stock Option Grant Notice

from 10-Q 23 pages Exclusive License Agreement Re: Bcm Blg # 13-040 Entitled “Methods for Inducing Selective Apoptosis”

from 10-Q 40 pages State of Texas County of Travis

from 10-Q 24 pages Exclusive License Agreement Baylor College of Medicine Bellicum Pharmaceuticals, Inc

from 10-Q 19 pages Exclusive License Agreement Baylor College of Medicine Bellicum Pharmaceuticals, Inc